Edition:
United Kingdom

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

17.43USD
15 Dec 2017
Change (% chg)

$0.13 (+0.75%)
Prev Close
$17.30
Open
$17.29
Day's High
$17.72
Day's Low
$17.07
Volume
382,358
Avg. Vol
172,765
52-wk High
$20.89
52-wk Low
$7.37

Latest Key Developments (Source: Significant Developments)

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Depomed Inc ::DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL.DEPOMED INC - RELOCATION OF COMPANY HEADQUARTERS MID-2018.DEPOMED INC - TRANSACTION IS IMMEDIATELY ACCRETIVE AND IMPROVES 2018 EBITDA OUTLOOK.DEPOMED - PLANS TO RELOCATE ITS CORPORATE HEADQUARTERS FROM NEWARK, SOMETIME IN MID-2018 & IS CURRENTLY EVALUATING POTENTIAL MIDWEST & EAST COAST LOCATIONS.DEPOMED INC - COMPANY WILL REDUCE ITS STAFF BY 40% TO APPROXIMATELY 70 EMPLOYEES AND HEADQUARTERS OFFICE SPACE REQUIREMENT BY 50%.DEPOMED INC - EXPECTS TO SAVE APPROXIMATELY $10 MILLION ANNUALLY AS A RESULT OF HEADQUARTERS RESTRUCTURING AND RELOCATION.DEPOMED INC - WILL ELIMINATE ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING ON NUCYNTA.DEPOMED INC - BY ELIMINATING ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING CO TO REDUCE SG&A EXPENSES BY ABOUT $70 MILLION ON AN ANNUAL BASIS.DEPOMED INC - UNDER TERMS OF AGREEMENT, COLLEGIUM WILL COMMERCIALIZE BOTH NUCYNTA EXTENDED RELEASE AND NUCYNTA IMMEDIATE RELEASE.DEPOMED INC - DEPOMED WILL RECEIVE A ROYALTY RATE ON ALL NUCYNTA REVENUES BASED ON CERTAIN NET SALES THRESHOLDS.  Full Article

Collegium To License Rights To Commercialize Nucynta Franchise
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE.COLLEGIUM PHARMACEUTICAL INC - DEAL IS IMMEDIATELY ACCRETIVE.COLLEGIUM PHARMACEUTICAL INC - ENTERED INTO A DEFINITIVE COMMERCIALIZATION AGREEMENT WITH DEPOMED.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY A MINIMUM ANNUAL LICENSE FEE OF $135.0 MILLION PAID QUARTERLY IN ARREARS.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL ALSO PAY DOUBLE-DIGIT ROYALTIES ON NET SALES ABOVE $233.0 MILLION PER YEAR.COLLEGIUM PHARMACEUTICAL - AFTER 12 MONTHS, CO MAY TERMINATE AGREEMENT WITH TWELVE MONTHS' NOTICE AND PAYMENT OF A $25.0 MILLION TERMINATION FEE.COLLEGIUM PHARMACEUTICAL INC - AFTER FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY DOUBLE-DIGIT ROYALTIES ON ALL NET SALES.COLLEGIUM PHARMACEUTICAL INC - TRANSACTION HAS BEEN APPROVED BY COLLEGIUM'S AND DEPOMED'S BOARD OF DIRECTORS.COLLEGIUM PHARMACEUTICAL INC - EXPECTS TO SUPPORT NUCYNTA FRANCHISE WITH ITS EXISTING RETAIL AND HOSPITAL FIELD FORCES.COLLEGIUM PHARMACEUTICAL INC - WILL RECEIVE AN EXCLUSIVE SUBLICENSE TO COMMERCIALIZE NUCYNTA AND NUCYNTA ER IN UNITED STATES.  Full Article

Collegium reports third quarter loss of $0.45 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Collegium Pharmaceutical Inc :Collegium reports third quarter financial results and provides corporate update.Q3 loss per share $0.45.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Collegium receives FDA approval for sNDA for Xtampza® ER
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Collegium Pharmaceutical Inc :Collegium receives FDA approval for sNDA for Xtampza® ER.  Full Article

Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Collegium Pharmaceutical Inc :Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER.Collegium Pharmaceutical - ‍FDA hasn't requested any additional scientific information or data regarding co's snda for Xtampza ER​.  Full Article

Sectoral Asset Management reports 7.4 percent passive stake in Collegium Pharmaceutical as of December 31, 2016
Friday, 10 Feb 2017 

Sectoral Asset Management Inc :Sectoral Asset Management reports a 7.4 percent passive stake in Collegium Pharmaceutical as of December 31, 2016 - SEC filing.  Full Article

Collegium reports Q2 loss per share $1.05
Wednesday, 10 Aug 2016 

Collegium Pharmaceutical Inc : Collegium reports second quarter financial results and provides corporate update . Q2 loss per share $1.05 . Q2 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S .Based on current operating plans, expect that existing cash resources will fund operations into early 2018.  Full Article

Collector Q2 profit after tax up at SEK 94 million
Wednesday, 20 Jul 2016 

Collector AB : Q2 total income 365 million Swedish crowns ($42.4 million) versus 296 million crowns year ago .Q2 profit after tax 94 million crowns versus 61 million crowns year ago.  Full Article

Collegium Pharma reports positive topline results for hydrocodone deterx clinical study
Wednesday, 22 Jun 2016 

Collegium Pharmaceutical Inc : Collegium announces positive topline results for hydrocodone deterx® clinical study . Plans to accelerate development of lead hydrocodone deterx formulation candidate .Results demonstrated that both hydrocodone deterx product candidates were bioequivalent when comparing crushed, intact dosing.  Full Article